ArticleBreast cancer (Tokyo, Japan)2016

Production and characterization of a novel long-acting Herceptin-targeted nanobubble contrast agent specific for Her-2-positive breast cancers.

Qiongchao Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.